



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 10 Apr 2018 (#10)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov).

**Confirm your intent to apply ASAP, but not later than 30 days before the submission date.**

Contact: RGMO Pre-Awards [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)

## Important notices:

- Findings of Research Misconduct ([NOT-OD-18-159](#)) Office of the Director, NIH
- Financial Conflict of Interest: Investigator Disclosures of Foreign Financial Interests ([NOT-OD-18-160](#)) Office of the Director, NIH
- Notice of National Institute of Allergy and Infectious Diseases (NIAID's) Interest in Continued Support of High Priority Immunology Grants ([NOT-AI-18-024](#))
- National Heart, Lung, and Blood Institute (NHLBI) Policy Regarding Submission of Clinical Trial Applications ([NOT-HL-18-611](#))
- [Opportunity To Join Collaborative Network for Autoimmune Disease Research](#) Basic and clinical researchers will collaborate to design and conduct studies of autoimmune disease pathogenesis and mechanisms of action of immune-modulating agents
- [FOA Supports Establishing Genomic Centers for Infectious Diseases](#)
- [New Online Reference Resource for Labs Conducting Tuberculosis Trials](#) The Mycobacteriology Laboratory Sourcebook for Harmonization and Support of Tuberculosis (TB) Clinical Trials helps ensure high-quality results and comparability of data across laboratories participating in TB clinical trials.
- [Request for Information on Laboratory Animal Care and Use](#) Share your feedback on how we can best harmonize laboratory animal regulations and policies to reduce the burden on you.

### 1. Accelerating Basic and Translational Research in Hidradenitis Suppurativa (Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-718\)](#)  
[\(PA-18-719\)](#)

**Type:** R21  
R01

**Application Due Date:** [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) will support basic and translational studies aimed at understanding the etiology, and the cellular and molecular mechanisms, including the environmental, genetic, epigenetic, biologic, and immunologic factors causing and/or associated with Hidradenitis Suppurativa. The purpose is to accelerate discovery in this field of research and to apply new knowledge to improve patients' condition and ultimately better control disease. This FOA intends to support a broad range of mechanistic studies using animal and human models, with an emphasis on multidisciplinary collaboration for rapid bench-to-bedside exchange of information and therapy development. This FOA is not intended to support applications proposing epidemiology studies and/or clinical trials.

**Budget:** R21 - The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. Applicants may request direct costs in \$25,000 modules, up to the total direct costs limitation of \$275,000 for the combined two-year award period.

R01 - Application budgets must reflect the actual needs of the proposed project and is limited to direct costs of no more than \$500,000 per year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

## 2. Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-722\)](#)  
[\(PA-18-723\)](#)

**Type:** R01  
R21

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This funding opportunity announcement (FOA) is being issued by the NIH Adherence Network through the Office of Behavioral and Social Sciences Research (OBSSR) with participation from multiple NIH Institutes and Centers. This FOA calls for research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider and/or healthcare system, and community levels. Attention to scientific rigor in all applications is paramount, with emphasis on appropriate sample sizes, valid outcome measures, and testing intervention mechanisms of action. The specific research interests of participating NIH Institutes and Centers are detailed within. This FOA accepts applications that either propose or do not propose a clinical trial(s).

**Budget:** R01 - Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period for this FOA is 5 years.

R21 - The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

## 3. Generating New Insights and Mechanistic Understanding of Antibiotic Resistance Development (Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-724\)](#)  
[\(PA-18-725\)](#)

**Type:** R21  
R01

**Application Due Date:** [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to advance select areas of research recognized as critical in the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), including research focused on understanding the nature of microbial communities, how antibiotics affect them, and how they can be harnessed to prevent disease, as well as research exploring combination therapies to address the emergence of resistance.

**Budget:** R21 - The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

R01 - Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

## 4. Research on the Health of Transgender and Gender Nonconforming Populations (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-728\)](#)  
[\(PA-18-729\)](#)

**Type:** R21  
R01

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This funding opportunity announcement (FOA) calls for research on the health of transgender and gender nonconforming people of all ages, including both youth and adults who are questioning their gender identity and those individuals who are making or who have made a transition from being identified as one gender to the other. This group encompasses individuals whose gender identity differs from the sex on their original birth certificate or whose gender expression varies significantly from what is traditionally associated with or typical for that sex.

**Budget:** R21 - Application budgets are not to exceed \$275,000 in direct costs for the entire duration of the grant. No more than \$200,000 may be requested in any single year.

R01 - Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

## 5. Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low and Middle- Income Countries (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PAR-18-732\)](#)

**Type:** R21

**Application Due Date:** August 1, 2018. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this FOA is to stimulate research on interventions to reduce HIV/AIDS-associated stigma and its impact on the prevention and treatment of HIV/AIDS and on the quality of life of People Living with HIV/AIDS (PLWH). Specifically, this initiative will support research on a) novel stigma reduction interventions that link to increase in care-seeking behavior and/or decrease in transmission; b) reducing the impact of stigma on adolescent and/or youth health; c) strategies to cope with the complex burden of stigmatization due to HIV and one or more comorbidities/co-infections; d) reducing effects of stigma on and/or by family members or caregivers of PLWH; and e) innovative and improved stigma measurement in the context of implementation of an intervention. The overall goals are to understand how to reduce stigma as a factor in HIV transmission, to eliminate or mitigate the aspects of stigma that limit beneficial health outcomes for the infected and at-risk individuals and communities, and to initiate exploratory studies to determine the feasibility of stigma interventions related to HIV prevention, treatment and/or care in Low and Middle-Income Countries (LMICs).

**Budget:** Application budgets are limited to up to \$125,000 per year in direct costs but need to reflect the actual needs of the proposed project. Applicants may request a project period of up to two years.

## 6. Small Research Grants for Analyses of Data for the Gabriella Miller Kids First Data Resource (Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PAR-18-733\)](#)

**Type:** R03

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotype data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. The overall goal of the Gabriella Miller Kids First Pediatric Data Resource is to help researchers understand the underlying mechanisms of these conditions, leading to more refined diagnostic capabilities and ultimately more targeted therapies, as well as to develop an integrated pediatric research data resource by obtaining and aggregating genome sequence and phenotype data for as many relevant structural birth defects and pediatric cancer cohorts as possible and to advance research in this area through the broad sharing of these data with the research community. This FOA is intended to promote meritorious small research projects focused on the development and analyses of childhood cancer and/or structural birth defects datasets that are part of the Kids First Data Resource or could be included in the Kids First Data Resource. Development of statistical methodology appropriate for analyzing genome-wide data relevant to childhood cancer and/or structural birth defects may also be proposed.

**Budget:** The combined budget for direct costs for the two year project period may not exceed \$200,000. A project duration of up to two years may be requested.

## 7. Small Research Grants for Establishing Basic Science-Clinical Collaborations to Understand Structural Birth Defects (Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PAR-18-734\)](#)

**Type:** R03

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this funding opportunity announcement (FOA) is to promote initial establishment of basic science-clinical collaborations by providing small grants to teams of basic scientists, physician scientists, and/or clinicians. These interdisciplinary teams may include but are not limited to the following: developmental biologists, cell biologists, geneticists, genomicists, physician scientists including individuals with DVM/VMD degrees, clinicians, epidemiologists, biostatisticians, and/or bioinformaticists. Applications must include at least one scientist with expertise from the basic science side of the spectrum as well as one from the clinical side. The multiple PD/PI model is strongly encouraged but not required. The goal is to facilitate the gathering of preliminary data to support future, larger research grant applications that will combine expertise and integrate basic, translational, and/or clinical approaches to understanding the developmental biology, genetics, and/or environmental basis of structural birth defects.

**Budget:** Application budgets for up to \$75,000 direct costs per year are allowed but should reflect the actual needs of the proposed project. The maximum project period is two years.

### Definitions of some NIH grant mechanisms:

[comprehensive list of extramural grant and cooperative agreement activity codes](#)

